Literature DB >> 1541966

Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study.

R Heun1, U Sliwka, H Rüttinger, K Schimrigk.   

Abstract

Fifty patients with multiple sclerosis were treated either by corticosteroids given systemically or by intrathecal injection of a steroid crystal suspension. Before and 3 weeks after the beginning of the treatment we examined the patients according to the Expanded Disability Status Scale (EDSS). Four patients had to be excluded from evaluation. In 23 patients the examination revealed at least a small improvement in their disability status. There were 7 intrathecally and 5 systemically treated patients whose disability was significantly reduced. One patient under intrathecal treatment showed a minor deterioration in disability. There was no clear difference in the frequency of improved symptoms or in EDSS scores between the two therapies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541966     DOI: 10.1007/bf00839208

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  35 in total

1.  Laboratory studies after intrathecal corticosteroids: determination of corticosteroids in plasma and cerebrospinal fluid.

Authors:  A D SEHGAL; D C TWEED; W J GARDNER; M K FOOTE
Journal:  Arch Neurol       Date:  1963-07

2.  Predictable remissions in multiple sclerosis.

Authors:  G J BOINES
Journal:  Del Med J       Date:  1963-08

3.  Subdural administration of hydrocortisone in multiple sclerosis: effect of ACTH.

Authors:  G F KAMEN; G L ERDMAN
Journal:  J Am Geriatr Soc       Date:  1953-11       Impact factor: 5.562

4.  Dangers from methylprednisolone acetate therapy by intraspinal injection.

Authors:  H Wilkinson
Journal:  Arch Neurol       Date:  1989-07

5.  Modifications of the cerebrospinal fluid IgG concentrations in patients with multiple sclerosis treated with intrathecal steroids.

Authors:  A R Massaro
Journal:  J Neurol       Date:  1978-12-22       Impact factor: 4.849

6.  [Evoked potentials with intrathecal and systemic corticosteroid therapy in multiple sclerosis].

Authors:  R Heun; W Emser; K Schimrigk
Journal:  EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb       Date:  1989-06

7.  Complications from methylprednisolone acetate (Depo-Medrol) when injected into the orbit, subarachnoid, or subdural spaces.

Authors:  R Abel; D A Nelson; J L Bernat
Journal:  Del Med J       Date:  1977-06

8.  Conus medullaris syndrome following multiple intrathecal corticosteroid injections.

Authors:  F L Cohen
Journal:  Arch Neurol       Date:  1979-04

Review 9.  Dangers from methylprednisolone acetate therapy by intraspinal injection.

Authors:  D A Nelson
Journal:  Arch Neurol       Date:  1988-07

10.  Disability rating scales in multiple sclerosis.

Authors:  J F Kurtzke
Journal:  Ann N Y Acad Sci       Date:  1984       Impact factor: 5.691

View more
  5 in total

1.  Long-Term Effects of Repeated Cycles of Intrathecal Triamcinolone Acetonide on Spasticity in MS Patients.

Authors:  Paulus Stefan Rommer; Frank Kamin; Mazen Abu-Mugheisib; Wolfgang Koehler; Frank Hoffmann; Alexander Winkelmann; Reiner Benecke; Uwe Klaus Zettl
Journal:  CNS Neurosci Ther       Date:  2015-11-20       Impact factor: 5.243

2.  Muscle rupture caused by exacerbated spasticity in a patient with multiple sclerosis.

Authors:  Robert Patejdl; Alexander Winkelmann; Reiner Benecke; Uwe Klaus Zettl
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

3.  Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a review.

Authors:  Mazen Abu-Mugheisib; Reiner Benecke; Uwe K Zettl
Journal:  Mult Scler Int       Date:  2011-06-26

4.  Efficacy of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients with spinal symptoms.

Authors:  Kerstin Hellwig; Franz Josef Stein; Horst Przuntek; Thomas Müller
Journal:  BMC Neurol       Date:  2004-11-07       Impact factor: 2.474

Review 5.  Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.

Authors:  Mickael Bonnan
Journal:  Mult Scler Int       Date:  2015-01-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.